What is HC Wainwright’s Estimate for Evolus FY2029 Earnings?

Evolus, Inc. (NASDAQ:EOLS – Free Report) – Equities researchers at HC Wainwright upped their FY2029 earnings per share (EPS) estimates for shares of Evolus in a research report issued on Thursday, November 5th. HC Wainwright analyst D. Tsao now anticipates that the company will earn $1.02 per share for the year, up from their prior forecast of $0.99. HC Wainwright currently has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Evolus’ current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Evolus’ FY2030 earnings at $1.36 EPS.

Several other analysts have also commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Evolus in a research report on Friday, September 11th. BTIG Research raised their price target on shares of Evolus from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, November 5th. Finally, Wall Street Zen raised shares of Evolus from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Evolus currently has a consensus rating of “Moderate Buy” and an average target price of $15.00.

Get Our Latest Stock Analysis on Evolus

Evolus Price Performance

EOLS opened at $6.63 on Monday. The business’s 50-day moving average is $7.56 and its two-hundred day moving average is $6.37. Evolus has a 1 year low of $3.86 and a 1 year high of $9.31. The firm has a market capitalization of $438.84 million, a PE ratio of -14.11 and a beta of 1.38.

Institutional Investors Weigh In On Evolus

Large investors have recently modified their holdings of the business. GAMMA Investing LLC raised its position in shares of Evolus by 65.6% in the 3rd quarter. GAMMA Investing LLC now owns 3,288 shares of the company’s stock valued at $26,000 after purchasing an additional 1,303 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Evolus in the 3rd quarter worth approximately $27,000. Legal & General Group Plc acquired a new stake in Evolus in the 2nd quarter worth approximately $40,000. Quantbot Technologies LP purchased a new stake in Evolus during the 2nd quarter worth approximately $56,000. Finally, Sequoia Financial Advisors LLC purchased a new stake in Evolus during the 2nd quarter worth approximately $71,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Insider Buying and Selling

In other Evolus news, insider David Moatazedi sold 105,108 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $9.04, for a total value of $950,176.32. Following the completion of the sale, the insider directly owned 499,592 shares in the company, valued at approximately $4,516,311.68. This trade represents a 17.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 5.00% of the company’s stock.

About Evolus

(Get Free Report)

Evolus, Inc. is a medical aesthetics company focused on developing and commercializing treatments for cosmetic procedures. The company’s portfolio includes injectable products used by healthcare professionals to address facial lines and wrinkles and to enhance facial appearance. Its flagship product, Jeuveau (prabotulinumtoxinA-xvfs), is a prescription botulinum toxin treatment for moderate to severe frown lines between the eyebrows in adults. Evolus also markets Evolysse, a line of hyaluronic acid dermal fillers designed for facial aesthetic treatments.

Recommended Stories

Earnings History and Estimates for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.